INDIANAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) and Adverum Biotechnologies, Inc. (ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition ...
Indianapolis-based Eli Lilly and Co. on Friday announced it is acquiring California-based Adverum Biotechnologies, a developer of gene therapies focused on age-related vision loss. Adverum is ...
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results